Intellect Neurosciences, J&J, Pfizer neurology news
Intellect filed an appeal with the European Patent Office regarding its decision to revoke European Patent No. 0,994,728, which is related to the company's Antisenilin technology and covers antibodies against beta amyloid and methods of treating Alzheimer's disease. The EPO revoked the patent in October 2011 following an opposition by Elan Corp. plc (NYSE:ELN, Dublin, Ireland), which argued that Intellect did not disclose claims to the use of recombinant antibodies in preventing or treating AD in its patent application. The EPO concluded that the application only disclosed the use of recombinant antibodies in situ by gene therapy and therefore the use in treating AD constitutes subject matter that extends beyond the application as filed. Intellect has corresponding patents for the technology in Japan and China and has patents pending in the U.S. ...